Comparison of Intralesional Triamcinolone Acetonide Injection versus Surgical Intervention for Management of Primary Chalazion
Doi: 10.36351/pjo.v38i4.1457
DOI:
https://doi.org/10.36351/pjo.v38i4.1457Abstract
Purpose: To compare the effectiveness of intralesional steroid injection versus Incision and curettage in management of primary chalazion.
Study Design: Quasi experimental study.
Place and Duration of Study: Department of Ophthalmology, Pakistan Institute of Medical Sciences, Islamabad, from August 2020 to January 2021.
Methods: Eighty patients were divided into two groups of 40 each through consecutive sampling. Patients with primary chalazion of the size >5mm, age group 18 to 50 years and either gender were included. Patients with recurrent, multiple and infected chalazia were excluded. All patients underwent complete ocular examination. Group A underwent Incision and curettage while in group B a 28 gauge needle with a 1 ml syringe was used to inject 0.25 ml of 40 mg/ml Triamcinolone Acetonide into the chalazion via transcutaneous route. Success was defined as 80% reduction in the size of chalazion after one month. The chi-square test was used for equivalence of treatment efficacy between the groups.
Results: Age range in this study was 18 to 50 years. Mean age was 34.10 ± 5.87 years in Group A and 35.975 ± 7.60 years in Group B. The procedure was successful in 31 (77.5%) individuals in group A and 33 (82.5%) individuals in group B (P = 0.576), which was statistically insignificant. Stratification with respect to gender and age also showed no statistically significant difference between the two groups (p > 0.05).
Conclusion: Intralesional steroid injection and Incision/curettageare equally effective in management of primary chalazion.
![](https://www.pjo.org.pk/public/journals/1/submission_1457_2157_coverImage_en_US.png)
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 Hafiz Muhammad Jahanzaib, ijaz Khan, Fahmina Nazir, Amina Khalid, Nida Armoghan
![Creative Commons License](http://i.creativecommons.org/l/by-nc/4.0/88x31.png)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.